Xenetic Biosciences, Inc.

Equities

XBIO

US9840156023

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
4.15 ^USD	-2.12%		+5.60%	+20.29%

05-22	Xenetic Biosciences, Inc. Announces Management Resignations	CI
05-22	Xenetic Biosciences, Inc. Announces Chief Executive Officer Changes	CI

XENETIC BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

January 19, 2021 at 08:03 am

Item 7.01. Regulation FD Disclosure.

Attached to this report as Exhibit 99.1 is the current corporate presentation of Xenetic Biosciences, Inc. (the "Company"), which the Company has prepared in anticipation of potential upcoming investor meetings. The presentation is furnished pursuant to this Item 7.01 and shall not be deemed filed in this or any other filing of the Company with the Securities and Exchange Commission, unless expressly incorporated by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits



Exhibit No. Description



99.1          2021 Corporate Presentation






























  2

Latest news about Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. Announces Management Resignations	05-22	CI
Xenetic Biosciences, Inc. Announces Chief Executive Officer Changes	05-22	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
CLS Therapeutics Discloses its Views on Xenetic Biosciences	03-18	CI
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform	01-17	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
North American Morning Briefing : Debt-Ceiling -2-	23-05-17	DJ
HC Wainwright Downgrades Xenetic Biosciences to Neutral From Buy	23-05-16	MT
Xenetic Biosciences to Implement 1-for-10 Reverse Split	23-05-12	MT
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Xenetic Biosciences, The Scripps Research Institute Enter Into Research Collaboration	23-04-11	MT
Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board	22-11-16	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Xenetic Biosciences, Inc. announced that it has received $0.488835 million in funding from CLS Therapeutics, LLC	22-10-12	CI
Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, LLC	22-10-11	CI
Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board	22-10-04	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Xenetic Biosciences, VolitionRx to Develop Adoptive Cell Therapies to Treat Cancer	22-08-02	MT
Xenetic Biosciences Signs Manufacturing Deal With Catalent Unit for Cancer Platform	22-07-07	MT
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding	22-05-03	CI
HC Wainwright Adjusts Price Target on Xenetic Biosciences to $4 From $5, Reiterates Buy Rating	22-05-02	MT
Xenetic Biosciences, Inc. Enters into Sublicense Agreement with CLS Therapeutics Ltd	22-04-27	CI

Chart Xenetic Biosciences, Inc.

Duration

Period

More charts

Company Profile

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Xenetic Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.15

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XENETIC BIOSCIENCES, INC.	+20.29%	6.53M
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.07%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-14.81%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.34%	14.08B

Bio Therapeutic Drugs